Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Alex Friedlaender

Showing results (31-40 of 106) with videos related to

Pageof 11
Sort By:
ESMO Open|April 5, 2020
How we treat patients with lung cancer during the SARS-CoV-2 pandemic: <i>primum non nocere</i>Giuseppe Banna, Alessandra Curioni-Fontecedro, Alex Friedlaender, et al.
Current Oncology Reports|November 27, 2019
Poor-Performance Status Assessment of Patients with Non-small Cell Lung Cancer Remains Vague and Blurred in the Immunotherapy EraAlex Friedlaender, Giuseppe Luigi Banna, Lucio Buffoni, et al.
ESMO Open|May 16, 2020
Reply to AuthorsGiuseppe Banna, Alessandra Curioni-Fontecedro, Alex Friedlaender, et al.
Lung Cancer Management|December 7, 2019
Identifying successful biomarkers for patients with non-small-cell lung cancerAlex Friedlaender, Joshua Bauml, Giuseppe Luigi Banna, et al.
Cancer Epidemiology|July 29, 2022
Trends in incidence and mortality of lung cancer in Switzerland: Possible explanations and open questionsDaniele Frisone, Jose Sandoval, Alex Friedlaender, et al.
Mediastinum (Hong Kong, China)|July 14, 2022
Home-deliverable antitumoral treatments in the age of COVID-19: the Portsmouth experience and a narrative reviewHiba Mechahougui, Harliana Yusof, Nathalie Baudoux, et al.
Current Oncology Reports|August 30, 2023
Cellular Therapy in NSCLC: Between Myth and RealityMartina Imbimbo, Laureline Wetterwald, Alex Friedlaender, et al.
Critical Reviews in Oncology/Hematology|June 3, 2020
A BRAF new worldDaniele Frisone, Alex Friedlaender, Umberto Malapelle, et al.
Critical Reviews in Oncology/Hematology|June 4, 2021
TMB or not TMB as a biomarker: That is the questionAlfredo Addeo, Alex Friedlaender, Giuseppe L Banna, et al.
Frontiers in Oncology|April 4, 2019
Next Generation Sequencing and Genetic Alterations in Squamous Cell Lung Carcinoma: Where Are We Today?Alex Friedlaender, Giuseppe Banna, Umberto Malapelle, et al.
Pageof 11

Showing results (31-40 of 106) with videos related to

Sort By:
Pageof 11
ESMO Open|April 5, 2020
How we treat patients with lung cancer during the SARS-CoV-2 pandemic: <i>primum non nocere</i>Giuseppe Banna, Alessandra Curioni-Fontecedro, Alex Friedlaender, et al.
Current Oncology Reports|November 27, 2019
Poor-Performance Status Assessment of Patients with Non-small Cell Lung Cancer Remains Vague and Blurred in the Immunotherapy EraAlex Friedlaender, Giuseppe Luigi Banna, Lucio Buffoni, et al.
ESMO Open|May 16, 2020
Reply to AuthorsGiuseppe Banna, Alessandra Curioni-Fontecedro, Alex Friedlaender, et al.
Lung Cancer Management|December 7, 2019
Identifying successful biomarkers for patients with non-small-cell lung cancerAlex Friedlaender, Joshua Bauml, Giuseppe Luigi Banna, et al.
Cancer Epidemiology|July 29, 2022
Trends in incidence and mortality of lung cancer in Switzerland: Possible explanations and open questionsDaniele Frisone, Jose Sandoval, Alex Friedlaender, et al.
Mediastinum (Hong Kong, China)|July 14, 2022
Home-deliverable antitumoral treatments in the age of COVID-19: the Portsmouth experience and a narrative reviewHiba Mechahougui, Harliana Yusof, Nathalie Baudoux, et al.
Current Oncology Reports|August 30, 2023
Cellular Therapy in NSCLC: Between Myth and RealityMartina Imbimbo, Laureline Wetterwald, Alex Friedlaender, et al.
Critical Reviews in Oncology/Hematology|June 3, 2020
A BRAF new worldDaniele Frisone, Alex Friedlaender, Umberto Malapelle, et al.
Critical Reviews in Oncology/Hematology|June 4, 2021
TMB or not TMB as a biomarker: That is the questionAlfredo Addeo, Alex Friedlaender, Giuseppe L Banna, et al.
Frontiers in Oncology|April 4, 2019
Next Generation Sequencing and Genetic Alterations in Squamous Cell Lung Carcinoma: Where Are We Today?Alex Friedlaender, Giuseppe Banna, Umberto Malapelle, et al.
Pageof 11